Finally, we tested whether demographic (age, sex, and educational level), genetic (APOE-ε4), and imaging markers (cortical thickness and white matter hyperintensities [WMHs]) are associated with between-person variability in CR and BR to pathological tau.12,13,14,15 On the basis of an emerging literature highlighting female-specific risks for developing AD,12,16,17,18,19 we were particularly interested in potential sex differences in resilience to pathological tau. The gene discussed is MAPT; the disease is Alzheimer disease.